NBIX Neurocrine Biosciences Inc
- Stocks
- Healthcare
- NASDAQ: NBIX
Price (delayed)
$153.75
Market cap
$15.33B
P/E Ratio
35.67
Dividend/share
N/A
EPS
$4.31
Enterprise value
$15.42B
Relative Growth:
Rel. Growth:
99
Relative Strength:
Rel. Strength:
74
Relative Valuation:
Rel. Valuation:
31
Relative Profitability:
Rel. Profitability:
92
Neurocrine Biosciences is a publicly traded biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological
Highlights
The price to earnings (P/E) is 62% lower than the 5-year quarterly average of 93.2
NBIX's EPS is up by 24% since the previous quarter and by 12% year-on-year
The debt has soared by 70% YoY but it is down by 2.4% QoQ
Neurocrine Biosciences's quick ratio has decreased by 27% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.neurocrine.com/
Key stats
What are the main financial stats of NBIX
Market
Valuations
Earnings
Shares outstanding
99.71M
Market cap
$15.33B
Enterprise value
$15.42B
Price to earnings (P/E)
35.67
Price to book (P/B)
5.08
Price to sales (P/S)
5.7
PEG
3.05
EV/EBIT
24.53
EV/EBITDA
22.7
EV/Sales
5.75
Revenue
$2.68B
Gross profit
$2.64B
Operating income
$550.2M
Net income
$428M
EBIT
$628.6M
EBITDA
$679.2M
Free cash flow
$593.1M
Per share
Balance sheet
Liquidity
EPS
$4.31
EPS diluted
$4.18
Free cash flow per share
$5.97
Book value per share
$30.28
Revenue per share
$26.99
TBVPS
$42.56
Total assets
$4.27B
Total liabilities
$1.26B
Debt
$428.4M
Equity
$3B
Working capital
$1.52B
Debt to equity
0.14
Current ratio
3.38
Quick ratio
2.89
Net debt/EBITDA
0.13
Margins
Efficiency
Dividend
EBITDA margin
25.3%
Gross margin
98.4%
Net margin
16%
Operating margin
20.5%
Return on assets
11%
Return on equity
15.8%
Return on invested capital
18%
Return on capital employed
17.3%
Return on sales
23.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NBIX stock price
How has the Neurocrine Biosciences stock price performed over time
Intraday
7.37%
1 week
11.4%
1 month
12.2%
1 year
26.51%
YTD
12.64%
QTD
9.52%
Financial performance
How have Neurocrine Biosciences's revenue and profit performed over time
Revenue
$2.68B
Gross profit
$2.64B
Operating income
$550.2M
Net income
$428M
Gross margin
98.4%
Net margin
16%
The company's net income rose by 23% QoQ and by 11% YoY
The operating margin has contracted by 21% YoY but it has grown by 4.1% from the previous quarter
Neurocrine Biosciences's revenue has increased by 20% YoY and by 7% QoQ
The gross profit has grown by 19% YoY and by 7% from the previous quarter
Price vs fundamentals
How does NBIX's price correlate with its fundamentals
Growth
What is Neurocrine Biosciences's growth rate over time
Valuation
What is Neurocrine Biosciences stock price valuation
P/E
35.67
P/B
5.08
P/S
5.7
EV/EBIT
24.53
EV/EBITDA
22.7
EV/Sales
5.75
The price to earnings (P/E) is 62% lower than the 5-year quarterly average of 93.2
NBIX's EPS is up by 24% since the previous quarter and by 12% year-on-year
NBIX's price to book (P/B) is 14% lower than its 5-year quarterly average of 5.9 but 8% higher than its last 4 quarters average of 4.7
The company's equity rose by 11% QoQ and by 10% YoY
Neurocrine Biosciences's revenue has increased by 20% YoY and by 7% QoQ
The stock's price to sales (P/S) is 16% less than its 5-year quarterly average of 6.8 but 12% more than its last 4 quarters average of 5.1
Efficiency
How efficient is Neurocrine Biosciences business performance
The ROE has grown by 20% from the previous quarter
Neurocrine Biosciences's return on assets has increased by 17% QoQ but it has decreased by 3.5% YoY
The company's return on invested capital rose by 13% QoQ
NBIX's return on sales is up by 11% since the previous quarter
Dividends
What is NBIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NBIX.
Financial health
How did Neurocrine Biosciences financials performed over time
The total liabilities has soared by 55% YoY and by 6% from the previous quarter
Neurocrine Biosciences's quick ratio has decreased by 27% YoY
The debt is 86% lower than the equity
The debt has soared by 70% YoY but it is down by 2.4% QoQ
NBIX's debt to equity has surged by 56% year-on-year but it is down by 13% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.